| Objective To investigate the efficacy of isosorbide mononitrate tablets and isosorbide mononitrate tablets combined with trimetazidine tablets in the treatment of chronic heart failure. Methods A total of 138 patients with chronic heart failure in our hospital were selected and divided into the control group and the observation group by double-blind method with 69 cases each. The control group was treated with isosorbide mononitrate tablets, while the observation group was treated with trimetazidine tablets, and both groups were treated continuously for six months. After six months of treatment, the clinical efficacy, cardiac function, inflammatory index, serum cathepsin S, platelet reactive protein-1, and brain natriuretic peptide levels of the two groups were compared, and the occurrence of adverse reactions was observed.Results The total clinical effective rate of the observation group(91.30%) was higher than that of the control group(81.16%), and the difference was statistically significant(P<0.05).The variations of cardiac function indicators, inflammatory cytokine indicators, Cat S, TSP-1, and BNP levels before and after treatment in the observation group was more obvious than that of the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(χ2=0.122, P=0.727). Conclusions Isosorbide mononitrate capsule combined with trimetazidine tablets can effectively improve cardiac function, reduce inflammatory reaction and improve the levels of serum Cat s, TSP-1 and BNP in patients with chronic heart failure. It has definite curative effect and high safety. |
